Premium
Development of the Membrane Autotransfusion System Prototype‐II: MATS‐II
Author(s) -
Fukunaga Ken,
Shimoyama Takashi,
Sawada Koji,
Sueoka Akinori,
Nosé Yukihiko
Publication year - 2000
Publication title -
artificial organs
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.684
H-Index - 76
eISSN - 1525-1594
pISSN - 0160-564X
DOI - 10.1046/j.1525-1594.2000.06434.x
Subject(s) - autotransfusion , hematocrit , plasmapheresis , hemoconcentration , membrane , biomedical engineering , chemistry , chromatography , surgery , medicine , blood transfusion , immunology , biochemistry , antibody
This article is the second of a two‐part series describing a membrane autotransfusion system, MATS, utilizing plasmapheresis technology. Based on experiences obtained from the first prototype (MATS‐I), optimum blood filtration parameters with refined blood and flux pump synchronization were put into an original CPU‐board and loaded on a miniaturized, self‐operative, and preclinical prototype (MATS‐II). This study was conducted to evaluate the MATS‐II using diluted blood of various hematocrit concentrations. The results proved that this device could concentrate 4,000–10,000 ml of various hematocrit concentrations into higher than 40% while automatically controlling the flow speed from 250 to 400 ml/min. Also, no significant damage was generated to the red blood cells (RBC). Moreover, the MATS‐II salvaged over 90% of platelets together with the RBC. These results suggest that the MATS‐II achieves all clinical requirements of an autotransfusion device; it is a continuous hemoconcentration device with minimum damage to cellular components of the blood.